Shares of the clinical-stage biotech Galectin Therapeutics (NASDAQ: GALT) are ripping higher today after the company announced a new patent covering the use of GR-MD-02 as a means to treat pulmonary fibrosis. The patent reportedly extends the experimental drug's period of exclusivity until 2032.As of 12:25 p.m. EDT, Galectin's shares still are up by a respectable 13.3% on the back of this news. Image source: Getty Images.Continue reading